The stock of FibroGen Inc (NASDAQ:FGEN) is a huge mover today! About 950,856 shares traded hands or 86.42% up from the average. FibroGen Inc (NASDAQ:FGEN) has declined 5.93% since April 8, 2016 and is downtrending. It has underperformed by 11.58% the S&P500.
The move comes after 6 months positive chart setup for the $1.66 billion company. It was reported on Nov, 10 by Barchart.com. We have $27.79 PT which if reached, will make NASDAQ:FGEN worth $531.20M more.
FibroGen Inc (NASDAQ:FGEN) Ratings Coverage
Out of 3 analysts covering FibroGen Inc (NASDAQ:FGEN), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. FibroGen Inc has been the topic of 6 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Buy” rating by Citigroup on Wednesday, July 29. Lake Street initiated the shares of FGEN in a report on Wednesday, September 23 with “Hold” rating. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Outperform” rating by Credit Suisse on Thursday, February 11. The rating was initiated by Citigroup with “Buy” on Friday, December 4. The stock of FibroGen Inc (NASDAQ:FGEN) earned “Neutral” rating by Credit Suisse on Thursday, January 21.
According to Zacks Investment Research, “FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.”
More news for FibroGen Inc (NASDAQ:FGEN) were recently published by: Quotes.Wsj.com, which released: “FibroGen Inc. FGEN (US: Nasdaq)” on November 08, 2014. Streetinsider.com‘s article titled: “Form 4 FIBROGEN INC For: Nov 08 Filed by: Yu K Peony” and published on November 09, 2016 is yet another important article.
FGEN Company Profile
FibroGen, Inc., incorporated on September 29, 1993, is a research biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Firm focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology and generates multiple programs targeting various therapeutic areas. The Company’s lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.